Summit Therapeutics Inc.

Phase 2 Confirmed

ivonescimab

first-line metastatic NSCLC, squamous tumors

Resolved

38days ago

Phase 2 readout · May 30, 2026

What's at stake Phase 2 trial results for ivonescimab in first-line metastatic NSCLC, squamous tumors are due May 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 17h ago

“Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in �rst-line metastatic colorectal cancer (mCRC) co-sponsored by Summit and Akeso, ”

Add to calendar Post on X Reddit

Provenance